Professional Documents
Culture Documents
Biocon India Group Case Study: Quantic MBA - April 2020 Cohort
Biocon India Group Case Study: Quantic MBA - April 2020 Cohort
Case Study
Quantic MBA – April 2020 Cohort
Main questions
• How might these advantages and disadvantages influence Biocon’s decision about whether to
aggressively invest in Clinigene?
Case overview
Manufacturing
• Increasing population
Fast growing demand
• Growing access
With these regulations in place, Indian players held a great advantage against global
players on the production of generic drugs but no incentive to conduct R&D on new drugs
for the internal market
Summary
Clinical trial industry in India have some further …but also face different challenges
incentives beyond the overall pharma…